1. Home
  2. BCG vs LIXT Comparison

BCG vs LIXT Comparison

Compare BCG & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BCG

Binah Capital Group Inc.

HOLD

Current Price

$1.69

Market Cap

32.6M

Sector

N/A

ML Signal

HOLD

Logo Lixte Biotechnology Holdings Inc.

LIXT

Lixte Biotechnology Holdings Inc.

HOLD

Current Price

$5.49

Market Cap

26.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCG
LIXT
Founded
2016
2005
Country
United States
United States
Employees
150
3
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.6M
26.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BCG
LIXT
Price
$1.69
$5.49
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
80.2K
63.5K
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$56.15
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.36
$0.64
52 Week High
$3.44
$6.09

Technical Indicators

Market Signals
Indicator
BCG
LIXT
Relative Strength Index (RSI) 35.88 67.95
Support Level $1.46 $3.77
Resistance Level $1.90 $6.03
Average True Range (ATR) 0.19 0.63
MACD -0.04 0.05
Stochastic Oscillator 5.62 82.72

Price Performance

Historical Comparison
BCG
LIXT

About BCG Binah Capital Group Inc.

Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Share on Social Networks: